日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe

欧洲利伐沙班长期上市后安全性研究项目面临的挑战和经验教训

Brobert, Gunnar; Ruigomez, Ana; Schink, Tania; Voss, Annemarie; Herings, Ron; Smits, Elisabeth; Swart, Karin M A; Friberg, Leif; Balabanova, Yanina; Tarenz, Christine; Suzart-Woischnik, Kiliana; Soriano-Gabarró, Montse; Vora, Pareen; Homering, Martin; Dyszynski, Tomasz; Nagel, Gerd; Amaya, Pablo; García Rodríguez, Luis Alberto

Risk of recurrent venous thromboembolism according to baseline risk factor profiles

根据基线风险因素评估复发性静脉血栓栓塞的风险

Prins, Martin H; Lensing, Anthonie W A; Prandoni, Paolo; Wells, Philip S; Verhamme, Peter; Beyer-Westendorf, Jan; Bauersachs, Rupert; Bounameaux, Henri; Brighton, Timothy A; Cohen, Alexander T; Davidson, Bruce L; Decousus, Hervé; Kakkar, Ajay K; van Bellen, Bonno; Pap, Akos F; Homering, Martin; Tamm, Miriam; Weitz, Jeffrey I

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty

利伐沙班与依诺肝素预防全髋关节或膝关节置换术后静脉血栓栓塞的获益风险评估

Levitan, Bennett; Yuan, Zhong; Turpie, Alexander G G; Friedman, Richard J; Homering, Martin; Berlin, Jesse A; Berkowitz, Scott D; Weinstein, Rachel B; DiBattiste, Peter M